tiprankstipranks
Advertisement
Advertisement

CLDX Stock Latest News

Celldex price target raised to $54 from $38 at Wells Fargo
The FlyCelldex price target raised to $54 from $38 at Wells Fargo
8d ago
CLDX
Celldex price target raised to $38 from $34 at Goldman Sachs
PremiumThe Fly
Celldex price target raised to $38 from $34 at Goldman Sachs
13d ago
CLDX
Celldex price target raised to $48 from $45 at Barclays
PremiumThe Fly
Celldex price target raised to $48 from $45 at Barclays
13d ago
CLDX
Celldex reports Q1 EPS ($1.18), consensus ($1.13)
PremiumThe Fly
Celldex reports Q1 EPS ($1.18), consensus ($1.13)
14d ago
CLDX
Celldex sees funds sufficient to fund current planned operations through 2028
PremiumThe Fly
Celldex sees funds sufficient to fund current planned operations through 2028
14d ago
CLDX
CLDX Earnings this Week: How Will it Perform?
PremiumPre-EarningsCLDX Earnings this Week: How Will it Perform?
23d ago
CLDX
Morning News Wrap-Up, 4/20/26: Today’s Biggest Stock Market Stories!
Premium
Market News
Morning News Wrap-Up, 4/20/26: Today’s Biggest Stock Market Stories!
1M ago
AMD
DIA
A Top Wall Street Analyst ‘Can’t Ignore’ Celldex Stock (CLDX)
Premium
Market News
A Top Wall Street Analyst ‘Can’t Ignore’ Celldex Stock (CLDX)
1M ago
CLDX
Celldex upgraded to Overweight from Underweight at Barclays
PremiumThe Fly
Celldex upgraded to Overweight from Underweight at Barclays
1M ago
CLDX
Celldex Announces Major Underwritten Public Equity Offering
PremiumCompany Announcements
Celldex Announces Major Underwritten Public Equity Offering
2M ago
8K
CLDX
Celldex 10.345M share Spot Secondary priced at $29.00
PremiumThe Fly
Celldex 10.345M share Spot Secondary priced at $29.00
2M ago
CLDX
Closing Bell Movers: Globalstar spikes on acquisition report
PremiumThe Fly
Closing Bell Movers: Globalstar spikes on acquisition report
2M ago
FC
AMZN
Celldex announces common stock offering, no amount given
PremiumThe FlyCelldex announces common stock offering, no amount given
2M ago
CLDX
Celldex data shows improvements across six DLQI Domains in barzolvolimab trials
Premium
The Fly
Celldex data shows improvements across six DLQI Domains in barzolvolimab trials
2M ago
CLDX
Celldex upgraded to Outperform from Peer Perform at Wolfe Research
Premium
The Fly
Celldex upgraded to Outperform from Peer Perform at Wolfe Research
2M ago
CLDX
Celldex price target raised to $34 from $30 at Goldman Sachs
PremiumThe Fly
Celldex price target raised to $34 from $30 at Goldman Sachs
3M ago
CLDX
Celldex: Barzolvolimab’s Durable Efficacy in Chronic Urticaria Underpins Buy Rating Ahead of Key Late-Stage Catalysts
PremiumRatings
Celldex: Barzolvolimab’s Durable Efficacy in Chronic Urticaria Underpins Buy Rating Ahead of Key Late-Stage Catalysts
3M ago
CLDX
Celldex presents new data from Phase 2 ColdU, SD Open Label Extension
PremiumThe Fly
Celldex presents new data from Phase 2 ColdU, SD Open Label Extension
3M ago
CLDX
Celldex price target raised to $44 from $43 at Morgan Stanley
PremiumThe Fly
Celldex price target raised to $44 from $43 at Morgan Stanley
3M ago
CLDX
Celldex price target raised to $68 from $58 at Stifel
PremiumThe FlyCelldex price target raised to $68 from $58 at Stifel
3M ago
CLDX
Celldex Therapeutics: Early EMBARQ Enrollment and 2026 Data Catalysts Underscore Attractive Risk‑Reward and Support Buy Rating
Premium
Ratings
Celldex Therapeutics: Early EMBARQ Enrollment and 2026 Data Catalysts Underscore Attractive Risk‑Reward and Support Buy Rating
3M ago
CLDX
Maintaining Buy on Barzolvolimab: Accelerated Clinical Execution, Best-in-Class Potential, and 2026 Catalyst-Driven Upside
Premium
Ratings
Maintaining Buy on Barzolvolimab: Accelerated Clinical Execution, Best-in-Class Potential, and 2026 Catalyst-Driven Upside
3M ago
CLDX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >